Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) with a price target of $2.00, indicating a potential upside of 94.17% from the current price.
• Another firm, HC Wainwright, also reiterated a "buy" rating, setting a higher price target of $9.00, contributing to a consensus "buy" rating among analysts.
• Lineage Cell Therapeutics has seen significant investment increases from major institutions, including a 39.8% boost in holdings by JPMorgan Chase during the last quarter.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They currently have a $2.00 target price on the stock. D. Boral Capital's price target suggests a potential upside of 61.94% from the company's previous close.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, June 23rd. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Lineage Cell Therapeutics currently has an average rating of "Buy" and an average target price of $4.20.

Lineage Cell Therapeutics Trading Down 3.5%

Shares of NYSEAMERICAN:LCTX traded down $0.0450 during trading on Thursday, reaching $1.2350. The stock had a trading volume of 1,488,409 shares, compared to its average volume of 1,924,514. Lineage Cell Therapeutics has a one year low of $0.3651 and a one year high of $1.31. The company has a market capitalization of $282.02 million, a P/E ratio of -6.86 and a beta of 1.66. The firm's 50-day simple moving average is $0.99 and its 200 day simple moving average is $0.69.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several hedge funds have recently made changes to their positions in the company. Kapitalo Investimentos Ltda acquired a new stake in shares of Lineage Cell Therapeutics during the second quarter worth about $25,000. Jump Financial LLC purchased a new position in Lineage Cell Therapeutics during the second quarter worth about $28,000. Cannon Global Investment Management LLC purchased a new position in Lineage Cell Therapeutics during the second quarter worth about $30,000. Integrity Alliance LLC. raised its holdings in Lineage Cell Therapeutics by 75.0% during the second quarter. Integrity Alliance LLC. now owns 35,000 shares of the company's stock worth $32,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in Lineage Cell Therapeutics during the second quarter worth about $35,000. Hedge funds and other institutional investors own 62.47% of the company's stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.